Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported purchases exceed sales by $189.5KOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Giordano Christopher Thomas | CEO | Jul 13 '26 | Option Exercise | $5.88 | 8,719 | $51,267 | 11,324 | Jul 14 07:29 PM |
| Rich Stuart | Chief Medical Officer | Dec 09 '25 | Buy | $10.22 | 2,500 | $25,542 | 5,266 | Dec 10 06:48 PM |
| Rich Stuart | Chief Medical Officer | Dec 08 '25 | Buy | $10.10 | 2,500 | $25,250 | 5,000 | Dec 10 06:48 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.